These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9541888)

  • 1. [Latanoprost--a new prostaglandin F2 alpha analog in therapy of glaucoma--an overview].
    Erb C; Messerli J; Flammer J
    Klin Monbl Augenheilkd; 1998 Jan; 212(1):2-12. PubMed ID: 9541888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Glaucoma therapy with prostaglandin F2 alpha derivatives].
    Diestelhorst M
    Ophthalmologe; 1997 Oct; 94(10):754-69. PubMed ID: 9432248
    [No Abstract]   [Full Text] [Related]  

  • 3. Latanoprost as a new horizon in the medical management of glaucoma.
    Stjernschantz J; Alm A
    Curr Opin Ophthalmol; 1996 Apr; 7(2):11-7. PubMed ID: 10163315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effectiveness of latanoprost for the treatment of pediatric glaucoma].
    Urban B; Bakunowicz-Lazarczyk A; Mrugacz M; Oziebło-Kupczyk M
    Klin Oczna; 2004; 106(1-2 Suppl):243-4. PubMed ID: 15510514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timolol + latanoprost: new preparation. Last-resort eye drops.
    Prescrire Int; 2003 Oct; 12(67):173-4. PubMed ID: 14619889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma.
    Hedner J; Svedmyr N; Lunde H; Mandahl A
    Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S111-5. PubMed ID: 9154286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
    Friström B; Uusitalo H
    Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment.
    Stjernschantz J
    Exp Eye Res; 2004 Apr; 78(4):759-66. PubMed ID: 15037110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies.
    Bayer A; Weiler W; Oeverhaus U; Skrotzki FE; Stewart WC;
    J Ocul Pharmacol Ther; 2004 Dec; 20(6):470-8. PubMed ID: 15684807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latanoprost: new preparation. Antiglaucoma eye drops that can change the colour of the iris.
    Prescrire Int; 1998 Dec; 7(38):166-8. PubMed ID: 10848045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospects of using latanoprost, prostaglandin F2 alpha analog, in hypotensive therapy for glaucoma].
    Egorov EA; Nesterov AP; Romanova OV
    Vestn Oftalmol; 1998; 114(4):19-20. PubMed ID: 9771080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment.
    Azuara-Blanco A; Katz LJ; Spaeth GL; Wilson RP; Moster MR; Flartey KJ
    Br J Ophthalmol; 1997 Dec; 81(12):1116. PubMed ID: 9497479
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of the use of latanoprost for glaucoma since its launch.
    Digiuni M; Fogagnolo P; Rossetti L
    Expert Opin Pharmacother; 2012 Apr; 13(5):723-45. PubMed ID: 22348427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma.
    Parmaksiz S; Yüksel N; Karabas VL; Ozkan B; Demirci G; Caglar Y
    Eur J Ophthalmol; 2006; 16(1):73-80. PubMed ID: 16496249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
    Traverso CE; Ropo A; Papadia M; Uusitalo H
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
    Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inner canthus hypertrichosis: a side effect of prostaglandin analogue treatment for glaucoma.
    Monselise A; Shapiro J; Lui H
    J Cutan Med Surg; 2011; 15(5):298-9. PubMed ID: 21962192
    [No Abstract]   [Full Text] [Related]  

  • 19. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population.
    Bhosle MJ; Reardon G; Camacho FT; Anderson RT; Balkrishnan R
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):100-11. PubMed ID: 17719512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
    Li N; Chen XM; Zhou Y; Wei ML; Yao X
    Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.